On October 31, we said Viking Therapeutics (VKTX) was a solid opportunity.

Especially as the company was set to jump into Obesity Week where the company was presenting results from its Phase 2 VENTURE clinical trial with its subcutaneous formulation of VK2735. It’s other presentation will highlight results from its Phase 1 multiple ascending dose clinical trial of its oral formulation of VK2735.

This morning, the stock is up about $12 a share after VKTX strong results for its experimental obesity pill, with increased weight loss observed at higher doses.

Headlines are leading traders to the slaughter. If you want the tools to outsmart the herd and fund your financial goals, click here.

“Patients on 100-milligram doses of Viking’s VK2735 lost an average of 8.2% of their body weight after 28 days in an early-stage study, or 6.8% more than those taking a placebo, the company said in a presentation at the Obesity Week meeting Sunday in San Antonio,” added Seeking Alpha. 

Plus, the company is about to start its Phase 2 study of the oral version of VK2735 before the end of the year. “The oral version is being developed as an alternative for patients hesitant for injection-based therapy, looking to maintain their weight loss, or transition away from the injectable version of VK2735.”

Moving forward, we’d like to see VKTX closer to $100 a share.

Sincerely,

Ian Cooper